Oncolys BioPharma's results for the 1-9 month period (cumulative third quarter) showed a narrower net loss year on year, while the loss widened in the July-September quarter.
Oncolys BioPharma announced in its preliminary earnings report that its net loss for the 1-9 month period (cumulative third quarter) had narrowed. Cumulative third-quarter revenue was 31 for 24.01-09, 28 for 25.01-09 and 527 for 26.01-09. Net income was negative in each period, but the loss was smaller than in the same period of the previous year.
In contrast, the quarterly results for July-September showed that the net loss had widened. The quarterly trend after the third quarter included periods in which the loss widened compared with the previous fiscal year. The year-on-year comparison for the cumulative third quarter is shown throughout as loss narrowing.
The current fiscal-year outlook includes a full-year forecast, with net income of -1,684 for 2024.12 and -2,058 for 2025.12. Quarterly results have alternated between widening and narrowing losses from 25.07-09 through 25.10-12, 26.01-03, 26.04-06 and 26.07-09.
Points to watch going forward include the trend in the loss through the end of the fiscal year, changes in adjusted earnings per share for the current and next fiscal years, and trends in adjusted dividends.